Theravance Biopharma, Inc. Announces Strategic Actions and R

Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments...

Related Keywords

United States , Dublin , Ireland , American , Maravai Lifesciences , Susannah Gray , Ricke Winningham , Theravance Biopharma , Williamd Young , Bloomberg , Merrill Lynch , American Autonomic Society , Theravance Biopharma Inc , Young , Columbia University , Company Annual Report On Form , Company Form , Development Rd Expenses , Securities Exchange , Capital Return Program , While Viatris Inc , Wesleyan University , Independent Director , Executive Vice President , Chief Financial Officer , Royalty Pharma , Independent Director William , General Meeting , Annual General Meeting , Chief Executive , Autonomic Society , Full Year Financial Results , Financial Guidance , Based Compensation , New Independent Director , Chase Securities , Molecular Therapeutics , Live Webcast Today , Private Securities Litigation Reform Act , Securities Exchange Act , Months Ended December , Ended December , Annual Report , While Viatris , Shareholder Equity , Virtual Poster , Nc ,